Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Liver Fibrosis – Pipeline Review, H2 2014” to its store. The report provides data on the Liver Fibrosis’s therapeutic pipeline.

Liver Fibrosis therapeutic Pipeline Review H2 2014

Liver Fibrosis therapeutic Pipeline Review H2 2014

Past News Releases

RSS

The report “Liver Fibrosis - Pipeline Review, H2 2014” provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html .

Companies discussed in this Liver Fibrosis – Pipeline Review, H2 2014 report include ACROVIS biostructures GmbH, Advinus Therapeutics Ltd., Angion Biomedica Corp., BiOrion Technologies B.V., Celgene Corporation, Digna Biotech, S.L., FibroGen, Inc., Galectin Therapeutics, Inc., Genfit SA, GenKyoTex S.A., Gilead Sciences, Inc., GNI Group Ltd., La Jolla Pharmaceutical Company, LG Life Sciences, Ltd., Nitto Denko Corporation, Pfizer Inc., Pharmaxis Limited, Promedior, Inc., Promethera Biosciences S.A., ProMetic Life Sciences Inc., RXi Pharmaceuticals Corporation, Silence Therapeutics plc, TCM Biotech International Corp and Virobay Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AbyD-3263, ANG-3281, ANG-3298, ANG-4011, BOT-162, BOT-191, CC-539, CC-90001, CIGB-500, CT-140, DB-036, disitertide, Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis, F-351, FG-3019, GCS-100, GFT-505, GKT-137831, GM-CT-01, GM-CT-02, GR-MD-01, GR-MD-02, HepaStem, KBP-7018, KW-0, LC-280126, LJPC-201, melittin, ND-L02s0201, NPLC-0393, P-17, PBI-4050, PRI-724, PRM-151, PXS-4728A, PXS-5033-A, RNAi Oligonucleotide for Hepatocellular Carcinoma, Ischemia Reperfusion Injury and Fulminant Fibrosis, RXI-209, simtuzumab, Small Molecule for Liver Fibrosis, Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis, Small Molecule to Inhibit NOX 1 and 4, Small Molecules for Liver Diseases, Small Molecules to Inhibit EGFR for Gastrointestinal Disorders, Stem Cell Therapy for Liver Fibrosis and Liver Diseases, Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology, TCM-808FB, TGFTX-4 Program, VBY-376 and VBY-825. Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=239901 . (This is a premium report priced at US$2000 for a single user License.)

List of Tables

Number of Products under Development for Liver Fibrosis, H2 2014 12
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20

List of Figures

Number of Products under Development for Liver Fibrosis, H2 2014 12
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Products, H2 2014 20
Assessment by Monotherapy Products, H2 2014 49
Number of Products by Top 10 Targets, H2 2014 50
Number of Products by Stage and Top 10 Targets, H2 2014 50
Number of Products by Top 10 Mechanism of Actions, H2 2014 53
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 53
Number of Products by Top 10 Routes of Administration, H2 2014 56
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 57
Number of Products by Top 10 Molecule Types, H2 2014 58
Number of Products by Stage and Top 10 Molecule Types, H2 2014 59

Explore more reports on Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website